Global Practice Variation in the Management of Clostridioides difficile Infections: An International Cross-Sectional Survey of Clinicians - Summary - MDSpire
Advertisement
Global Practice Variation in the Management of Clostridioides difficile Infections: An International Cross-Sectional Survey of Clinicians
To evaluate global practice variability in the diagnosis, treatment, and prophylaxis of Clostridioides difficile infections (CDIs) among healthcare professionals, focusing on specific management aspects.
Key Findings:
75.8% of respondents used a 2-step CDI diagnostic algorithm, with variability in assay types indicating a need for standardization.
Significant differences were observed in first-line treatment agents for uncomplicated CDI, highlighting a lack of consensus on fulminant CDI management.
Secondary CDI prophylaxis was most common in North America (84.1%), contrasting with Europe (31.0%) and other continents (50.0%; P < .001), suggesting regional practice disparities.
Oral vancomycin was the most frequently used treatment (96.3%), with variability in dosing (125–500 mg daily) and duration (1–28 days; P < .01), indicating a need for clearer guidelines.
Interpretation:
The findings indicate substantial global variability in CDI management practices, likely due to conflicting guidelines and insufficient evidence, underscoring the need for further research to inform clinical practice.
Limitations:
Survey responses may not fully represent all healthcare professionals managing CDIs globally, potentially limiting the generalizability of the findings.
Potential biases in self-reported practices and limited response rates from certain regions may affect the reliability of the data.
Conclusion:
There is a critical need for randomized controlled trials to establish harmonized international best practices for CDI management, addressing the identified variability.
A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.
The expert panel outlines surveillance, device management, and diagnostic stewardship strategies to address both catheter-associated and non–catheter-associated infections.
